Earlier today, Sanofi-aventis (NYSE: SNY) announced that the FDA has approved Multaq 400 mg Tablets for patients with atrial fibrillation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE